BHVN Stock Analysis: Biohaven | NYSE
Biotechnology | NYSE, USA | Market Cap: 1.628m USD | 12M Return: -10.9% | VGG1110E1079 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 22.5M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut, focused on discovering, developing, and commercializing therapies across immunology, neuroscience, and oncology worldwide. The company was incorporated in 2022 and adopted its current name from Biohaven Research Ltd. in September 2022.
Biohaven operates a diversified pipeline spanning multiple development stages, including Phase 3 candidates such as BHV-8000 for Parkinsons disease and Opakalim for focal epilepsy, several Phase 2 and Phase 1 assets targeting indications like Graves disease, IgA nephropathy, peripartum cardiomyopathy, pain disorders, obesity, and various cancers, and a preclinical portfolio spanning autoimmune, neurological, and metabolic conditions.
As a biotechnology company in the healthcare sector, Biohaven follows a development-driven business model common to small-cap biopharma firms, where long R&D timelines, regulatory milestones, and future commercialization of approved therapies drive long-term value. The companys small market capitalization reflects its pre-commercial status, with revenue potential tied to successful trial outcomes and regulatory approvals.
- BHV-8000 Phase 3 Parkinsons data readout approaches
- Opakalim Phase 3 epilepsy results near-term stock catalyst
- Cash burn raises dilution risk as pipeline expands
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -1.32 > 0.02 and ΔFCF/TA -12.38 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -1.38 > 3% & CFO -511.4m > Net Income -586.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (150.6m) vs 12m ago 47.15% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.70%; Δ -0.70% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.63 (Total Current Assets 296.6m - Total Current Liabilities 62.7m) / Total Assets 370.7m |
| B: -6.35 (Retained Earnings -2.35b / Total Assets 370.7m) |
| C: -1.27 (EBIT TTM -585.6m / Avg Total Assets 460.6m) |
| D: 0.03 (Book Value of Equity 12.2m / Total Liabilities 358.5m) |
| Altman-Z'' = -25.05 = D |
As of October 23, 2026, the stock is trading at USD 14.69 with a total of 30,491,335 shares traded. Over the past week, the price has changed by +28.52%, over one month by -1.08%, over three months by -0.41% and over the past year by -10.86%.
Current recommended Stop Loss: 12.70 (which is 13.5% or 2.6 ATR below the current price).
Biohaven has received a consensus analysts rating of 4.18. Therefore, it is recommended to buy BHVN.
- StrongBuy: 9
- Buy: 3
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 21.3 | 44.8% |
P/B = 168.9387
Revenue TTM = 0.0 USD
EBIT TTM = -585.6m USD
EBITDA TTM = -575.3m USD
Long Term Debt = 259.5m USD (from longTermDebt, last quarter)
Short Term Debt = 4.67m USD (from shortTermDebt, last quarter)
Debt = 334.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 37.6m
Net Debt = 66.7m USD (calculated: Debt 334.6m - CCE 267.9m)
Enterprise Value = 1.69b USD (1.63b + Debt 334.6m - CCE 267.9m)
Interest Coverage Ratio = unknown (Ebit TTM -585.6m / Interest Expense TTM 0.0)
EV/FCF = -3.45x (Enterprise Value 1.69b / FCF TTM -491.1m)
FCF Yield = -28.97% (FCF TTM -491.1m / Enterprise Value 1.69b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.14m) / Revenue TTM)
Tobins Q-Ratio = 4.57 (Enterprise Value 1.69b / Total Assets 370.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 334.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -462.6m (EBIT -585.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.97 (Total Current Assets 296.6m / Total Current Liabilities 74.8m)
Debt / Equity = 27.38 (Debt 334.6m / totalStockholderEquity, last quarter 12.2m)
Debt / EBITDA = -0.12 (negative EBITDA) (Net Debt 66.7m / EBITDA -575.3m)
Debt / FCF = -0.14 (negative FCF - burning cash) (Net Debt 66.7m / FCF TTM -491.1m)
Total Stockholder Equity = 44.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -127.4% (out of range, set to none)
RoE = -1.33k% (out of range, set to none) (Net Income TTM -586.8m / Total Stockholder Equity 44.2m)
RoCE = -192.9% (out of range, set to none) (EBIT -585.6m / Capital Employed (Equity 44.2m + L.T.Debt 259.5m))
RoIC = -147.9% (out of range, set to none) (NOPAT -462.6m / Invested Capital 312.7m)
WACC = 8.88% (E(1.63b)/V(1.96b) * Re(10.70%) + D(334.6m)/V(1.96b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.82 | Cagr: 31.32%
[DCF] Fair Price = unknown (Cash Flow -491.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.22 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.16 | Chg30d=+180.14% | Revisions=-17% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.65 | Chg30d=+16.32% | Revisions=-17% | GrowthEPS=+70.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.87 | Chg30d=+3.36% | Revisions=+0% | GrowthEPS=-13.5% | GrowthRev=-45.7%
[Analyst] Revisions Ratio: -15% (up=4, down=6)